{"id":"https://genegraph.clinicalgenome.org/r/b835ff0b-43d5-41ad-b1ea-aaa14f5bc75fv1.1","type":"EvidenceStrengthAssertion","dc:description":"DPM2 was first reported in relation to autosomal recessive congenital muscular dystrophy with intellectual disability and severe epilepsy (also known as congenital disorder of glycosylation, type Iu) in 2012 (Barone et al, PMID: 23109149). 5 variants (splice site, missense, nonsense) that have been reported in 4 probands are included in this curation. Patients have a range of symptoms, including acquired microcephaly, facial dysmorphism, respiratory distress, congenital contractures, scoliosis, hypotonia, and lack of psychomotor development. The disease mechanism is thought to be biallelic loss of function. Heterozygous carriers are unaffected. This gene-disease relationship is supported by DPM2's interaction with DPM1 and DPM3, the other members of the DPM synthase complex, as well as an animal model (PMID: 27291147). Co-transfection and immunoprecipitation experiments suggest that DPM2 is the regulatory subunit of this complex (PMIDs: 9724629, 10835346). In summary, there is moderate evidence to support this gene-disease relationship. While more evidence is needed to establish this relationship definitively, no convincing contradictory evidence has emerged.\n\nThis classification was approved by the ClinGen Congenital Disorders of Glycosylation GCEP on the meeting date March 20, 2024 (SOP Version 10).","dc:isVersionOf":"https://genegraph.clinicalgenome.org/r/b835ff0b-43d5-41ad-b1ea-aaa14f5bc75f","GCISnapshot":"https://genegraph.clinicalgenome.org/r/7a5c5381-1dba-4c06-803b-4c40f9da85d6","calculatedEvidenceStrength":"Moderate","changes":[{"id":"cg:summaryChange"},{"id":"cg:otherTextChange"},{"id":"cg:classificationChange"},{"id":"cg:newEvidence"}],"contributions":[{"id":"https://genegraph.clinicalgenome.org/r/7a5c5381-1dba-4c06-803b-4c40f9da85d6_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10135","date":"2024-03-20T17:00:00.000Z","role":"Approver"},{"id":"https://genegraph.clinicalgenome.org/r/7a5c5381-1dba-4c06-803b-4c40f9da85d6_publish_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10135","date":"2024-04-17T18:21:11.586Z","role":"Publisher"}],"curationReasons":["NewCuration"],"evidence":[{"id":"https://genegraph.clinicalgenome.org/r/7a5c5381-1dba-4c06-803b-4c40f9da85d6_experimental_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/7a5c5381-1dba-4c06-803b-4c40f9da85d6_functional_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/df1998a5-e2c6-492c-9557-271922a18b2f","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/21567001-efe7-4efe-99dd-af2e218796ac","type":"Finding","dc:description":"DPM2 associates with DPM1 to form an enzyme complex. In addition, DPM2 is necessary for DPM1 to localize to the endoplasmic reticulum, and DPM2 enhances the binding of Dol-P to the DPM synthase complex.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/9724629","rdfs:label":"Interaction with DPM1","demonstrates":{"id":"obo:MI_0915"}}],"specifiedBy":"GeneValidityProteinInteractionCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/6acd3775-580a-4326-b6bd-36924b9c034b","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/8e331b18-c4df-4e01-be0e-14d46ee2455a","type":"Finding","dc:description":"DPM2 directly interacts with DPM3 and stabilizes it. DPM synthase activity is higher when DPM2 is cotransfected with DPM3. ","dc:source":"https://pubmed.ncbi.nlm.nih.gov/10835346","rdfs:label":"Interaction with DPM3","demonstrates":{"id":"obo:MI_0915"}}],"specifiedBy":"GeneValidityProteinInteractionCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/1e41a848-9321-48c2-87a8-2c515eea7c2c","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/9a873ae0-631a-4b72-8476-174cc1d2f354","type":"Finding","dc:description":"10835346, 9535917","dc:source":"https://pubmed.ncbi.nlm.nih.gov/9724629","rdfs:label":"Dol-P binding to DPM synthase","demonstrates":{"id":"cg:BiochemicalFunctionA"}}],"specifiedBy":"GeneValidityBiochemicalFunctionCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallFunctionalEvidenceCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/7a5c5381-1dba-4c06-803b-4c40f9da85d6_functional_alteration_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/fa1e0f7e-d072-45ce-8971-5a95a750c6a2","type":"EvidenceLine","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/fa5f0079-ea2c-4d14-8e74-45f792edf5be","type":"FunctionalAlteration","dc:description":"Decreased ICAM-1 expression in patient fibroblasts.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33129689","rdfs:label":"ICAM expression in patient cells"}],"specifiedBy":"GeneValidityPatientCellFunctionalAlterationCriteria","strengthScore":1}],"specifiedBy":"GeneValidityOverallFunctionalAlterationEvidenceCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/7a5c5381-1dba-4c06-803b-4c40f9da85d6_model_rescue_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/673154dd-994b-4335-843a-1bf801ef32a9","type":"EvidenceLine","dc:description":"Downgraded due to only examining the muscle phenotype and not the other phenotypic features present in humans with DPM2 mutations.","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/e2f5a1e8-7866-44d2-8370-badfb3788fd4","type":"Finding","dc:description":"Both zebrafish and humans exhibit a reduction in DPMS complex activity and skeletal muscle defects.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/27291147","rdfs:label":"Zebrafish Model","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":1}],"specifiedBy":"GeneValidityOverallModelAndRescueEvidenceCriteria","strengthScore":1}],"specifiedBy":"GeneValidityOverallExperimentalEvidenceCriteria","strengthScore":3.5},{"id":"https://genegraph.clinicalgenome.org/r/7a5c5381-1dba-4c06-803b-4c40f9da85d6_overall_genetic_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/cd24504f-56eb-423e-b282-702e0c4a26c9_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/cd24504f-56eb-423e-b282-702e0c4a26c9","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/37152991","rdfs:label":"Zhao Proband","ageType":"AgeAtReport","ageUnit":"Years","ageValue":11,"allele":{"id":"https://genegraph.clinicalgenome.org/r/1898a2a7-b18e-46e5-979b-d607a62b0876","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_003863.4(DPM2):c.197G>A (p.Gly66Glu)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA374958086"}},"detectionMethod":"Trio-WES was confirmed by Sanger","ethnicity":{"id":"cg:NotHispanicOrLatino"},"firstTestingMethod":"Exome sequencing","phenotypeFreeText":"brain MRI scan showed slightly longer patchy signals on T1 and T2, high intensity signals in the FLAIR (fluid-attenuated inversion recovery) sequence in the white matter of bilateral parietal lobes","phenotypes":["obo:HP_0002205","obo:HP_0001263","obo:HP_0001999","obo:HP_0000486","obo:HP_0003236","obo:HP_0001249"],"previousTestingDescription":"serum CK and CK-MB elevated","secondTestingMethod":"Sanger sequencing","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/b508c1c1-1f1d-4316-afc3-88eafa4a07fc_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/37152991","allele":{"id":"https://genegraph.clinicalgenome.org/r/1898a2a7-b18e-46e5-979b-d607a62b0876"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}},{"id":"https://genegraph.clinicalgenome.org/r/b508c1c1-1f1d-4316-afc3-88eafa4a07fc","type":"EvidenceLine","calculatedScore":0.2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/b508c1c1-1f1d-4316-afc3-88eafa4a07fc_variant_evidence_item"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.2}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":0.2},{"id":"https://genegraph.clinicalgenome.org/r/2f128ce8-825b-481e-97f3-960b69e1e4d5_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/2f128ce8-825b-481e-97f3-960b69e1e4d5","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33129689","rdfs:label":"Radenkovic Patient 1","ageType":"AgeAtDiagnosis","ageUnit":"Years","ageValue":19,"allele":[{"id":"https://genegraph.clinicalgenome.org/r/a3d9cdb0-4d9b-4dba-8aae-06ca5b549da0","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_003863.4(DPM2):c.139C>T (p.Arg47Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA374960035"}},{"id":"https://genegraph.clinicalgenome.org/r/cceab04f-493d-4166-a225-ef59f0530caa","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_003863.4(DPM2):c.173G>A (p.Gly58Asp)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA374959670"}}],"detectionMethod":"Variants identified in WES were confirmed with Sanger sequencing","firstTestingMethod":"Exome sequencing","phenotypes":["obo:HP_0033526","obo:HP_0001249","obo:HP_0001290","obo:HP_0003202","obo:HP_0001647","obo:HP_0000252","obo:HP_0001263","obo:HP_0001533"],"previousTestingDescription":"serum TIEF mildly abnormal, whole genome microarray normal, elevated serum creatine kinase, decreased ICAM1 expression in patient fibroblasts, decreased LAMP2 expression in patient fibroblasts, MALDI-TOF MS N-glycan analysis was normal, glycomics analysis revealed increases in Transferrin Mono-oligo/Di-oligo (0.38) and A-oligo/Di-oligo (0.019) ratio","secondTestingMethod":"Sanger sequencing","sex":"Male","variant":[{"id":"https://genegraph.clinicalgenome.org/r/9bda27f4-3776-4849-ae01-b50a8818b372_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33129689","allele":{"id":"https://genegraph.clinicalgenome.org/r/cceab04f-493d-4166-a225-ef59f0530caa"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}},{"id":"https://genegraph.clinicalgenome.org/r/2fe78813-8a57-417d-919c-96a58241ab5d_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33129689","allele":{"id":"https://genegraph.clinicalgenome.org/r/a3d9cdb0-4d9b-4dba-8aae-06ca5b549da0"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}}]},{"id":"https://genegraph.clinicalgenome.org/r/2fe78813-8a57-417d-919c-96a58241ab5d","type":"EvidenceLine","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/2fe78813-8a57-417d-919c-96a58241ab5d_variant_evidence_item"}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/9bda27f4-3776-4849-ae01-b50a8818b372","type":"EvidenceLine","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/9bda27f4-3776-4849-ae01-b50a8818b372_variant_evidence_item"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.1}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":1.6},{"id":"https://genegraph.clinicalgenome.org/r/7a5c5381-1dba-4c06-803b-4c40f9da85d6_seg_el","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/46fd4755-c0d0-4c39-9164-1def45435f82_proband_segregation","type":"FamilyCosegregation","dc:description":"Not enough affected individuals to score segregation.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/23109149","rdfs:label":"Barone Family","estimatedLodScore":0.98,"family":{"id":"https://genegraph.clinicalgenome.org/r/46fd4755-c0d0-4c39-9164-1def45435f82","type":"Family","rdfs:label":"Barone Family","member":{"id":"https://genegraph.clinicalgenome.org/r/695eba7f-268d-4635-98fd-f2c5027fff24","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/23109149","rdfs:label":"Barone Patient 2","ageType":"AgeAtDeath","ageUnit":"Months","ageValue":16,"allele":{"id":"https://genegraph.clinicalgenome.org/r/99514e4a-13ba-4a38-b3e4-62f6c20c21bf","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_003863.4(DPM2):c.68A>G (p.Tyr23Cys)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA130300"}},"detectionMethod":"DPM1, DPM2, and DPM3 were sequenced after excluding variants in POMT1, POMT2, POMGNT1, FKRP, FKTN, and LARGE)","firstTestingMethod":"Sanger sequencing","previousTesting":true,"previousTestingDescription":"Persistent elevated serum creatine kinases, Lipid-linked oligosaccharide analysis showed accumulation of Dol-PP-GlcNac2Man5 (similar to other CDG-1s)","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/a8c8efc1-0758-494d-95ec-fcdf16581b64_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/23109149","allele":{"id":"https://genegraph.clinicalgenome.org/r/99514e4a-13ba-4a38-b3e4-62f6c20c21bf"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"paternityMaternityConfirmed":"No","zygosity":{"id":"cg:Homozygous"}}}},"meetsInclusionCriteria":false,"phenotypeNegativeAlleleNegative":3,"phenotypePositiveAllelePositive":2,"phenotypes":["obo:HP_0002240","obo:HP_0011169","obo:HP_0001321","obo:HP_0002205","obo:HP_0000243","obo:HP_0000648","obo:HP_0002910","obo:HP_0000601","obo:HP_0040288","obo:HP_0011968","obo:HP_0000294","obo:HP_0002803","obo:HP_0002643","obo:HP_0000253","obo:HP_0002650","obo:HP_0002518","obo:HP_0005484","obo:HP_0002421","obo:HP_0006829","obo:HP_0003241","obo:HP_0000218","obo:HP_0001263","obo:HP_0001999","obo:HP_0000486","obo:HP_0000347","obo:HP_0001250","obo:HP_0000219"],"proband":{"id":"https://genegraph.clinicalgenome.org/r/695eba7f-268d-4635-98fd-f2c5027fff24"}}],"specifiedBy":"GeneValiditySegregationEvidenceCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/695eba7f-268d-4635-98fd-f2c5027fff24_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/695eba7f-268d-4635-98fd-f2c5027fff24"},{"id":"https://genegraph.clinicalgenome.org/r/a8c8efc1-0758-494d-95ec-fcdf16581b64","type":"EvidenceLine","calculatedScore":0.2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/a8c8efc1-0758-494d-95ec-fcdf16581b64_variant_evidence_item"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.2}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":0.2},{"id":"https://genegraph.clinicalgenome.org/r/10e3a7e3-e883-4369-88cc-516186e7bc41_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/10e3a7e3-e883-4369-88cc-516186e7bc41","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/23109149","rdfs:label":"Barone Patient 1","ageType":"AgeAtDeath","ageUnit":"Months","ageValue":36,"allele":[{"id":"https://genegraph.clinicalgenome.org/r/e80b5680-0215-4f98-86f8-2d4a3ae165f8","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_003863.4(DPM2):c.4-1G>C","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA130302"}},{"id":"https://genegraph.clinicalgenome.org/r/99514e4a-13ba-4a38-b3e4-62f6c20c21bf"}],"detectionMethod":"Targeted sequencing - CDG-I genes (ALG3, DPM1, DPM3, MPDU1) were negative, followed by DPM2 sequencing.","ethnicity":{"id":"cg:NotHispanicOrLatino"},"firstTestingMethod":"Sanger sequencing","phenotypes":["obo:HP_0002643","obo:HP_0000347","obo:HP_0000601","obo:HP_0005484","obo:HP_0000648","obo:HP_0000243","obo:HP_0003241","obo:HP_0002205","obo:HP_0001250","obo:HP_0001263","obo:HP_0011968","obo:HP_0000218","obo:HP_0002803","obo:HP_0002910","obo:HP_0000219","obo:HP_0002240","obo:HP_0002421","obo:HP_0001999","obo:HP_0002518","obo:HP_0000294","obo:HP_0040288","obo:HP_0011169"],"previousTesting":true,"previousTestingDescription":"Elevated serum transaminases and blood creatine kinase, decreased plasma antithrombin activity. Serum transferrin isoelectric focusing revealed abnormal N-glycosylation of serum transferrin (fig 2A), consistent with a type I CDG.","sex":"Female","variant":[{"id":"https://genegraph.clinicalgenome.org/r/66646ce0-d13e-44ab-b9ca-20559babf9e1_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/23109149","allele":{"id":"https://genegraph.clinicalgenome.org/r/e80b5680-0215-4f98-86f8-2d4a3ae165f8"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}},{"id":"https://genegraph.clinicalgenome.org/r/f7ee0172-b0f0-43e1-8c72-e0573228b5b9_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/23109149","allele":{"id":"https://genegraph.clinicalgenome.org/r/99514e4a-13ba-4a38-b3e4-62f6c20c21bf"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}}]},{"id":"https://genegraph.clinicalgenome.org/r/f7ee0172-b0f0-43e1-8c72-e0573228b5b9","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/f7ee0172-b0f0-43e1-8c72-e0573228b5b9_variant_evidence_item"},{"id":"https://genegraph.clinicalgenome.org/r/f7ee0172-b0f0-43e1-8c72-e0573228b5b9_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"PMID: 10835346 shows that this tyrosine is important for the interaction of DPM2 with DPM3, as shown by the drastic reduction in co-precipitating protein when Tyr23 is mutated (fig 4A).","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/66646ce0-d13e-44ab-b9ca-20559babf9e1","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/66646ce0-d13e-44ab-b9ca-20559babf9e1_variant_evidence_item"},{"id":"https://genegraph.clinicalgenome.org/r/66646ce0-d13e-44ab-b9ca-20559babf9e1_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"cDNA analysis showed that this mutation results in skipping of exon 2. DPM synthase activity was less than 10% in this patient.","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":2}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":2.5}],"specifiedBy":"GeneValidityOverallGeneticEvidenceCriteria","strengthScore":4.5}],"evidenceStrength":"Moderate","sequence":8191,"specifiedBy":"GeneValidityCriteria10","strengthScore":8,"subject":{"id":"https://genegraph.clinicalgenome.org/r/vdNeNqJSCFw","type":"GeneValidityProposition","disease":"obo:MONDO_0014023","gene":"hgnc:3006","modeOfInheritance":"obo:HP_0000007"},"version":"1.1","websiteLegacyID":"https://genegraph.clinicalgenome.org/r/assertion_7a5c5381-1dba-4c06-803b-4c40f9da85d6-","@context":{"@vocab":"https://genegraph.clinicalgenome.org/terms/","id":"@id","type":"@type","cg":"https://genegraph.clinicalgenome.org/terms/","dc":"http://purl.org/dc/terms/","obo":"http://purl.obolibrary.org/obo/","hgnc":"https://identifiers.org/hgnc:","rdfs":"http://www.w3.org/2000/01/rdf-schema#","cggv":"https://genegraph.clinicalgenome.org/r/gci/","evidenceStrength":{"@type":"@vocab"},"calculatedEvidenceStrength":{"@type":"@vocab"},"computedEvidenceStrength":{"@type":"@vocab"},"specifiedBy":{"@type":"@vocab"},"evidence":{"@container":"@set"},"disease":{"@type":"@vocab"},"gene":{"@type":"@vocab"},"phenotypes":{"@type":"@id"},"agent":{"@type":"@id"},"role":{"@type":"@vocab"},"modeOfInheritance":{"@type":"@vocab"},"sex":{"@type":"@vocab"},"direction":{"@type":"@vocab"},"ageType":{"@type":"@vocab"},"ageUnit":{"@type":"@vocab"},"dc:source":{"@type":"@id"},"curationReasons":{"@type":"@vocab","@container":"@set"},"GCISnapshot":{"@type":"@id"},"dc:isVersionOf":{"@type":"@id"},"websiteLegacyID":{"@type":"@id"}}}